Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

203
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
203
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271
Autoimmune Disorders01:29

Autoimmune Disorders

677
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
677
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

193
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
193
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

397
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
397
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

239
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
239

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Foxp3<sup>+</sup> Tregs in HCC immunity and immunotherapy.

Trends in molecular medicine·2026
Same author

Actin-specific smooth muscle antibodies bridge adult and juvenile autoimmune hepatitis diagnosis.

JHEP reports : innovation in hepatology·2026
Same author

Sepsis in Frail Older Adults: Tailored Antimicrobial Stewardship and Individualized Care Approach.

Antibiotics (Basel, Switzerland)·2026
Same author

An International Phase 4 Study of Lenvatinib and Sorafenib in Real-World Patients with Unresectable Hepatocellular Carcinoma: Final Analysis.

Liver cancer·2026
Same author

Primary biliary cholangitis: current insights and novel therapies.

Expert review of clinical immunology·2026
Same author

Structured CEUS-based diagnostic pathway for newly detected splenic lesions: impact on diagnostic latency and advanced imaging use in a multicenter quality improvement study, with exploratory discrimination between hematologic and non-hematologic disease.

Internal and emergency medicine·2026

Related Experiment Video

Updated: Sep 13, 2025

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

19.4K

Autoimmune Hepatitis Treatment: Can Low-Dose Steroids Be Generalized?

Alessandro Granito1,2, Paolo Muratori3,4, Albert J Czaja5

  • 1Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, S. Orsola-Malpighi Hospital, Via Albertoni 15, 40138, Bologna, Italy. alessandro.granito@unibo.it.

Digestive Diseases and Sciences
|July 25, 2025
PubMed
Summary

This letter questions the broad applicability of low- versus high-dose prednisolone induction findings in autoimmune hepatitis (AIH). The study

Keywords:
Autoimmune hepatitis (AIH)Biochemical responseCorticosteroidRemission

More Related Videos

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
11:36

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

3.1K
Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome
05:18

Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome

Published on: May 26, 2023

1.5K

Related Experiment Videos

Last Updated: Sep 13, 2025

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

19.4K
Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
11:36

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

3.1K
Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome
05:18

Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome

Published on: May 26, 2023

1.5K

Area of Science:

  • Hepatology
  • Immunology
  • Internal Medicine

Background:

  • Autoimmune hepatitis (AIH) management involves corticosteroids like prednisolone.
  • Recent studies explore optimal induction dosing strategies for AIH.
  • Aggarwal et al. investigated low- versus high-dose prednisolone for AIH induction.

Discussion:

  • The patient cohort in Aggarwal et al. was predominantly cirrhotic and often decompensated.
  • Advanced liver disease may significantly impact treatment response and side effect profiles.
  • Findings from this specific cohort may not generalize to the broader AIH population.

Key Insights:

  • Low- and high-dose prednisolone efficacy might not be equivalent across all AIH patients.
  • The severity of liver disease is a critical factor in corticosteroid treatment outcomes.
  • Current evidence may be insufficient to establish universally applicable dosing strategies.

Outlook:

  • Future AIH research should focus on diverse patient cohorts representing the full disease spectrum.
  • Establishing universally applicable corticosteroid dosing requires broader clinical trial data.
  • Further studies are needed to refine prednisolone induction protocols for varied AIH presentations.